Status:
COMPLETED
Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes
Diabetes Mellitus, Type 2
Eligibility:
All Genders
18-80 years
Phase:
PHASE3
Brief Summary
This trial is conducted in Africa, Asia, Europe and South America. This trial is designed to show the effect of treatment with liraglutide added to existing glimepiride and metformin combination thera...
Eligibility Criteria
Inclusion
- Type 2 diabetes
- Treatment with oral anti-diabetic drugs for at least 3 months
- HbA1c: 7.5-10.0 % (both incl.) in subjects on OAD monotherapy. 7.0-10.0 % (both incl.) in subjects on OAD combination therapy.
- Body Mass Index (BMI) less than or equal to 45 kg/m2
Exclusion
- Treatment with insulin within the last 3 months
- Treatment with any drug that could interfere with the glucose level
- Any serious medical condition
- Females who are pregnant, have intention of becoming pregnant or are breastfeeding
Key Trial Info
Start Date :
May 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2007
Estimated Enrollment :
584 Patients enrolled
Trial Details
Trial ID
NCT00331851
Start Date
May 1 2006
End Date
April 1 2007
Last Update
January 26 2017
Active Locations (116)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Bahía Blanca, Argentina, 8000
2
Novo Nordisk Investigational Site
Ciudad Autonoma de Bs As, Argentina, C1405CWB
3
Novo Nordisk Investigational Site
Junín, Argentina, 6000
4
Novo Nordisk Investigational Site
Mendoza, Argentina, 5500